natgillin/translations-raw huggingface dataset:
A compound which is 2-(3,5-Dichloro-1-oxido-pyridin-4-yl)-1-{9-difluoromethoxy-spiro[2H-1,5-benzodioxepin-3(4H),3'-oxetane]-6-yl}ethanone, or a pharmaceutically acceptable hydrate or solvate thereof, for use in the treatment of proliferative and inflammatory skin disorders such as psoriasis, epidermal inflammation, acne, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, urticaria, pruritis and eczema. 
PATENTNI ZAHTJEVI Spoj koji je 2-(3,5-Dikloro-1-oksido-piridin-4-il)-1-(9-difluorometoksi-spiro[2H-1,5-benzodioksepin-3(4H),3'- oksetan]-6-il)etanon, ili farmaceutski prihvatljiv hidrat ili solvat istoga, za uporabu u liječenju proliferativnih i upalnih kožnih poremećaja poput psorijaze, epidermalne upale, akni, dermatitisa, atopijskog dermatitisa, seboreičnog dermatitisa, kontaktnog dermatitisa, urtikarije, pruritisa i ekcema.
The method according to claim 8, wherein the processing of the cocoa pulp and mucilage comprises neutralizing and/or removing acidic components. 
Komplet za proizvodnju čokolade ili čokoladi sličnih proizvoda u skladu s patentnim zahtjevom 6, naznačen time što se u navedenom postupku obrada kakaove pulpe i biljne sluzi sastoji u neutraliziranju i/ili uklanjanju kiselih komponenata.
The compound for use according to any one of claims 6-7, wherein said administration comprises about 3mg to about 20mg of a compound of Formula I. 
Spoj za uporabu sukladno patentnom zahtjevu 13, pri čemu navedena primjena naloksona smanjuje simptome predoziranja ili toksičnosti prije primjene spoja.
a vector as defined above, and 
(i) vektor prema zahtjevu 6, i
Use according to claim 12, wherein the individual has a disease or disorder is selected from the group consisting of relapsing multiple sclerosis and chronic progressive multiple sclerosis, preferably wherein the individual has relapsing multiple sclerosis. 
Uporaba prema zahtjevu 11, naznačena time što pojedinac ima bolest ili poremećaj odabran iz skupine koja se sastoji od relapsirajuće multiple skleroze i kronične progresivne multiple skleroze, poželjno pri čemu pojedinac ima relapsirajuću multiplu sklerozu.
A compound of any one of claims 1 to 7, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of depression, bipolar disorder and anxiety. 
Tvar iz patentnog zahtjeva 1, ili njena farmaceutski prihvatljiva sol dobivena adicijom kiseline, za uporabu u liječenju depresije, bipolarnog poremećaja 1 tjeskobe u sisavaca.
Use of the antibody according to claims 1 to 7 for the manufacture of a medicament for the treatment of bone loss. 
Upotreba protutijela prema patentnim zahtjevima od 1 do 5, naznačena time, da je za proizvodnju lijeka za liječenje gubitka kostiju.
The communication method according to one of claims 6 to 9, wherein the first component carrier is a primary cell and the second component carrier is a secondary cell. 
Komunikacijski postupak u skladu s jednim od zahtjeva 7 do 11, naznačen time što je prvi nosač komponenti primarna stanica, a drugi nosač komponenti je sekundarna stanica.
A cancer chemotherapeutic agent according to any of (1) to (4) above, which is a compounding agent. 
Protutumorsko kemoterapijsko sredstvo u skladu s patentnim zahtjevom 1, naznačeno time, da je to kombinacijsko sredstvo.
Substantially perpendicularly to the base 14 there extends, towards the sole 2, a second appendix 20, constituting said adjusting and guiding means of the axial position with respect to the sole 2, slidably positionably at the first seat 9 provided on the upper surface 10 of the sole 2. 
Uglavnom okomito prema osnovici 14 prema potplatu 2 ide drugi nastavak 20, koji tvori spomenuto sredstvo za podešavanje i vođenje aksijalnog položaja u odnosu na potplat 2, a može se klizno namjestiti na prvi dosjed 9 postavljen na gornjoj površini 10 potplata 2.
Kit-of-parts combination, comprising at least one freeze-dried molded article according to any one of the embodiments 1 to 18 or 22, as well as at least one aqueous solution comprising one or more active substances and/or, optionally, one or more auxiliary substances, in a combined spatial arrangement. 
Kombinacija dijelova koja sadrži barem jedan liofilizirani oblikovani proizvod sukladno jednom od zahtjeva 1 do 6, 8, 9 ili je dobiven postupkom sukladno zahtjevu 7, kao i vodena otopina jedne ili više aktivnih supstanci i/ili, po mogućnosti, jedne ili više pomoćnih supstanci, u konjugiranom prostornom rasporedu.
decreased expression of one or more genes specific to the cell that the NSLC was obtained from (e.g. see Table C); 
- < smanjenu ekspresiju jednog ili više gena specifičnih za stanicu prvog tipa;
A process for preparing a compound of formula I, 
PATENTNI ZAHTJEVI 5 Postupak dobivanja spoja formule I
Method according to claim 6, further comprising the phase of disconnecting the load (16) from the network (10) whenever, during the phase of cyclical verifying of the regular detection of leakage currents, the maximum in modulus of the magnitude of the acquired proportional signal (90u) is greater than the sum of the limit-value and the zero-reference value. 
7. Postupak u skladu sa zahtjevom 6, naznačen time da slijedi faza odspajanja trošila (16) od mreže (10) kada je god, za vrijeme faze periodike provjere regularnog otkrivanja parazitne struje, najveći modul veličine dobivenog proporcionalnog signala (90u) veći od zbroja granične vrijednosti i vrijednosti nulte reference. m
The formulation of claim 22, wherein the binding agent is: or 
Formulacija prema zahtjevu 22, naznačena time da je sredstvo za vezanje: o f
A compound of general formula (I) according to any one of claims 1 to 6 wherein Y is a bivalent radical having the following meaning: straight or branched C2-C6 alkylene being substituted with —ONO2 or T, wherein T is as defined in claim 1; 
Spoj opće formule (I) prema bilo kojem od patentnih zahtjeva 1 do 2, naznačen time da Y jest dvovalentni radikal koji ima sljedeće značanje: a) - ravni ili razgranati C,-C4 alkilen koji može biti supstituiran s -ONO, ili T, gdje T jest kao što je definirano u patentnom zahtjevu 1,
One subject matter of the invention provides a method for the removal of nitrogen from natural gas by distillation, in which: 
HR P20180610 T1 PATENTNI ZAHTJEVI Postupak uklanjanja dušika iz zemnog plina destiliranjem, gdje: i)
In some embodiments the proliferative disorder is cancer. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 13, naznačen time što je proliferativni poremećaj rak.
a mouse anti-human FGFR2 monoclonal antibody conjugated on a microsphere; 
mišje anti-humano FGFR2 monoklonsko protutijelo konjugirano na mikrosferu;
A compound for use according to claim 17 wherein the compound is for administration as part of a combination therapy with an agent for treatment of diabetes, obesity, dyslipidaemia, or hypertension. 
Spoj za uporabu prema zahtjevu 17, naznačen time, da spoj se primjenjuje kao dio kombinacijske terapije sa sredstvom za liječenje dijabetesa, pretilosti, dislipidemije ili hipertenzije.
from about 35% to about 45% w/w of sofosbuvir wherein greater than 70% of the sofosbuvir is crystalline and the crystalline sofosbuvir has XRPD 2θ-reflections (° ±0.2θ) at about: 6.1, 12.7, 20.1 and 20.8; 
[image] i amorfan je; od oko 35% do oko 45% masenog udjela sofosbuvira koji ima formulu: [image] gdje je sofosbuvir kristalni i kristalni sofosbuvir ima XRPD 2θ-refleksije (°± 0.2θ) na: 6.1 i 12.7;
The product was collected by filtration and washed on the filter until snow-white using pet-ether (30-40°C) (40 to 60 ml) before air-drying at room temperature to yield B-DHTBZ (10.1 g, 67%) as a white solid. 
Produkt se sakupi filtriranjem i ispire se na filteru do snježno-bijelog uporabom petrolej etera (30-40 "C) (40 do 60 ml) prije sušenja zrakom na sobnoj temperaturi da bi se dobio f-DHTBZ (10.1 g, 67%) kao bijela krutina.
Once the temperature at the distillation head reached 75°C, the pot was allowed to cool. 
Nakon što je temperatura u destilacijskoj glavi dostigla 75*C, lonac je ostavljen da se hladi.
The container according to any one of the previous claims, wherein the fluid guide element is in the form of a line. 
Spremnik u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navodeći element za fluid (16, 17, 18) u obliku linije.
The process of paragraph 1, wherein the functional filler is present in an amount ranging from about 50% to about 70% by weight of the waste polymer. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što funkcionalno punilo dolazi u rasponu količina od 50% do 70%, težinski, otpadnog polimera.
or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof; 
(I s o ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese; obradi spoja formule (5):
A double stranded RNAi agent of claim 1 or a pharmaceutical composition of claim 6 or 7 for use in a method of reducing the accumulation of misfolded Serpinal in the liver of a subject having a Serpinal deficiency variant. 
Dvolančano RNAi sredstvo prema zahtjevu 1 ili farmaceutski pripravak prema zahtjevu 6 ili 7 za uporabu u postupku za smanjenje nakupljanja pogrešno složenog Serpinal u jetri subjekta koji ima varijantu nedostatka Serpinal.
A watch system comprising a holding assembly for gem positioning according to claim 8, wherein it comprises a lower disc for holding the gem holding and positioning assembly and the assembly containing the watch movements. 
Sustav ručnog sata, koji sadrži držaći sklop za smještavanje dragulja u skladu s patentnim zahtjevom 8, naznačen time što sadrži donji disk (22), za držanje sklopa za držanje i smještavanje dragulja (19), i sklop (18), koji sadrži mehanizam ručnog sata.
Diagnostic tests, which make use of the polymerase chain reaction (PCR) to detect the number of CAG repeats on the IT-15 gene, are now widely available and allow a prediction to be made whether or not a patient will develop the symptoms of Huntington's disease; see for example the review by M. Hayden et al., Am J. Hum. 
Dijagnostički testovi, koji koriste polimeraza lančanu reakciju (PCR) za otkrivanje broja CAG ponavljanja u TT-15 genu su sada opće raspoloživi i omogućavaju predviđanje hoće li ili neće pacijent razviti simptome Huntington-ove bolesti; vidi na primjer članak M. Hayden 1 sur., Am. J. Hum.
The oral pharmaceutical composition for use of claim 6, wherein the ratio of protease to lipase is 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, or 10:1. 
1, ili 20: 1. Oralno farmaceutski spoj za za uporabu sukladno zahtjevu 6, naznačena time, što je omjer ukupne proteaze prema ukupnoj lipazi 4: 1, 5: 1, 6: 1, 7: 1,8: 1,9: 1,1li 10: 1.
In order to produce a conductive flooring the following materials were used: Conductive silver glass spheres (CSGS 10 A, available from Progessive Fillers Intl Inc. of Tennessee, USA) having a mean particle size of 10 um, a pure silver plating of 12% and a dry bulk resisitivty of 0.001 Ohms/cm 
Za proizvodnju vodljive podne obloge korišteni su sljedeći materijali: 1) Vodljive posrebrene staklene kuglice (CSGS 10 A, dostupne od tvrtke Progessive Fillers Int'I Inc. Tennessee, SAD) srednje veličine čestica od 10 um, 12%-tni premaz od čistog srebra s električnim otporom u suhom nasipnom volumenu veličine 0,001 Ohm-cm.
The heat engine of claim 13, further comprising a positive displacement hydraulic pump for providing continuous flow of the refrigerant in the liquid phase from the low-pressure zone to the high-pressure zone. 
Toplinski motor prema Zahtjevu 13, koji dalje sadrži hidrauličnu pumpu s pozitivnim izmještanjem radi osiguravanja kontinuiranog toka rashladnog sredstva u tekućoj fazi iz zone niskog tlaka u zonu visokog tlaka.
R9, for each occurrence, is, independently, halo, lower alkyl, lower haloalkyl, lower alkoxy, lower haloalkoxy, or hydroxyl; and 
Ro, za svako pojavljivanje, je, nezavisno, halo, Cy-Cy alkil, C;-Ca haloalkil, Cy-Ca alkoksi, C,-Ca haloalkoksi, ili hidroksil; i
The compound of claim 12 wherein R1 is optionally substituted (C6-C10)aryl or optionally substituted (C1-C10)heteroaryl. 
Spoj u skladu s patentnim zahtjevom 12, naznačen time, da R1 je po izboru supstituirani (C6-C10)aril ili po izboru supstituirani (C1-C10)heteroaril.
at least one pore in the parylene coating, wherein the at least one pore extends from an outer surface of the parylene coating to the surface of the head portion of the body. 
najmanje jedna pora u parilenskoj oblozi, gdje se najmanje jedna pora pruža od vanjske površine parilenske obloge do površine glave tijela.
a second closure member arranged so as to be vertically movable relative to the inner tube and configured to seal the inner tube; and an actuation unit designed to control the vertical movement of the first closure member and the second closure member; 
drugi dio za zatvaranje (66) organiziran da bude vertikalno pomičan i zatvara unutarnju cijev (26); i jedinica za pokretanje (62) konfigurirana da kontrolira vertikalno pomicanje prvog elementa za zatvaranje i drugog elementa za zatvaranje (66);
The liquefied gas treatment system according to claim 4, wherein the sub LNG supply line (L24) further includes a heater (47) configured to adjust a temperature of the fuel, of which the methane number is adjusted by the gas-liquid separator, to a value necessary for the sub engine. 
Postupak obrade ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se, kada se LNG uskladišten u spremniku za teret dovodi u pomoćni motor, teške ugljikovodike kao komponentu odvaja od LNG-a kako bi se podesilo metanski broj L.NG-a do vrijednosti potrebne za pomoćni motor.
Component B) is metazachlor. 
Spojevi koji su obuhvaćeni komponentom B) su slijedeći.
In one aspect, the invention provides an immunobinder comprising one of the following solubility enhancing motifs in the heavy chain amino acid positions 12, 103 and 144 (AHo numbering): 
HR P20171250 T1 PATENTNI ZAHTJEVI no Imunovezno sredstvo, naznačeno time, da obuhvaća sljedeće motive pojačanja topivosti na aminokiselinskim pozicijama 12, 103 i 144 jakog lanca (AHo-numeriranje):
A method of preparing a compound of formula (I): or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof, wherein the method comprises: 
Postupak dobivanja spoja formule (I): ili njegove farmaceutski prihvatljive sol, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, naznačen time što se postupak sastoji u: reakciji spoja formule (2):
The preparation a has at least 1% of glycosaminoglycans, hydrolysed glycosaminoglycans, glycosamines, or chemically modified glycosaminoglycan, hydrolysed glycosaminoglycans, glycosamines with cyclic polycarbonates or with Pre-polymer of polyhydroxyurethanes terminated by cyclic carbonates functions (PRE-CC) or a blend of those different constituents in a blend containing acceptable solvents and optionally CC monomers of PHU or PRE-CC or a blend of PRE-CC and CC to ensure that the preparation a contains cyclic carbonate functions, and 
pripravak a ima barem 1 % glikozaminoglikana, hidroliziranih glikozaminoglikana, glikozamina ili kemijski modificiranih glikozaminoglikana, hidroliziranih glikozaminoglikana, glikozamina s cikličkim polikarbonatima ili s Pre-polimerom polihidroksiuretana terminiranog funkcijama cikličkih karbonata (PRE-CC) ili mješavinu spomenutih različitih sastojaka u mješavini koja sadrži prihvatljiva otapala i izborno CC monomere od PHU ili PRE-CC ili mješavinu PRE-CC i CC kako bi se osiguralo da pripravak a sadrži funkcije cikličkih karbonata, i
A dihydrate of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one according to any one of claims 1 to 6 for use in preventing and/or treating a central nervous system disease. 
Dihidrat 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoksi]-1H-kinolin-2-ona prema bilo kojem od zahtjeva 1 do 6 naznačen time da je za uporabu za liječenje 1/1li sprječavanje bolesti središnjeg živčanog sustava.
A pharmaceutical composition comprising an excipient and a therapeutically effective amount of a compound or therapeutically acceptable salt thereof of claim 1. 
Farmaceutski pripravak, naznačen time, da sadržava inertni nosač 1 terapeutski učinkovitu količinu spoja ili terapeutski prihvatljivu sol u skladu s patentnim zahtjevom 1 ili 2.
The method comprises contacting the biological sample together with two or more primers in a nucleic acid amplification reaction, performing a nucleic acid amplification reaction, then detecting the amplicon. The presence of the amplicon is diagnostic for said event DNA in the sample so long as the amplicon contains at least one of the contiguous sequences as set forth at SEQ ID NO:1 and SEQ ID NO:2, from about nucleotide position 1-11 or 9-20, or the complementary sequences corresponding to these positions. 
(b) osiguravanje uvjeta za reakciju amplifikacije nukleinske kiseline; (c) izvođenje reakcije amplifikacije nukleinske kiseline, pri čemu se dobiva amplikon DNA molekule; 1 (d) detektiranje navedenog amplikona DNA molekule, pri čemu otkrivanje amplikona koji sadrži najmanje jednu od SEQ ID NO: 1, SEQ ID NO: 2 i njenih komplemenata ukazuje na prisutnost navedene DNA molekule u spomenutom biološkom uzorku.
The pharmaceutical composition according to claim 1, further comprising at least one additional peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO 1, and SEQ ID NO 4 to SEQ ID NO 12. 
Farmaceutski sastav prema zahtjevu 1, koji nadalje uključuje najmanje jedan dodatni peptid koji sadrži slijed aminokiselina odabranog iz skupine koja se sastoji od SEQ ID NO 1 te SEQID NO 4 do SEQ ID NO 12.
is a carboxyl protecting group. 
P> je karboksilna zaštitna skupina.
A kit comprising a conjugated nucleic acid molecule according to claim 1 and a DNA-damaging anti-tumoral agent, as a combined preparation for simultaneous, separate or sequential use. 
Komplet, naznačen time što sadrži konjugiranu molekulu nukleinske kiseline u skladu s patentnim zahtjevom 2 1li 4 1 protutumorsko sredstvo koje oštećuje DNA, kao kombinirani pripravak za istodobnu, odvojenu ili uzastopnu upotrebu.
is a hydrogen atom; a hydroxy group; a straight or branched C1-C6 alkyl group unsubstituted or substituted with a straight or branched C1-C5 alkyl group, a halogen atom, a straight or branched C1-C5 alkoxy group, or a straight or branched C1-C3 thioalkyl group; a halogen atom; a straight or branched C1-C6 alkoxy group unsubstituted or substituted with a straight or branched C1-C5 alkyl group, a halogen atom, a straight or branched C1-C5 alkoxy group, or a straight or branched C1-C3 thioalkyl group; or a straight or branched C1-C4 thioalkyl group unsubstituted or substituted with a straight or branched C1-C5 alkyl group, a halogen atom, a straight or branched C1-C5 alkoxy group, or a straight or branched C1-C3 thioalkyl group; 
je atom vodika; hidroksi grupa; ravna ili razgranata C1-C6 alkil grupa nesupstituirana ili supstituirana sa ravnom ili razgranatom C1-C5 alkil grupom, atomom halogena, ravnom ili razgranatom C1-C5 alkoksi grupom, ili ravnom ili razgranatom C1-C3 tioalkil grupom; atom halogena; ravna ili razgranata C1-C6 alkoksi grupa nesupstituirana ili supstituirana sa ravnom ili razgranatom C1-C5 alkil grupom, atomom halogena, ravnom ili razgranatom C1-C5 alkoksi grupom, ili ravnom ili razgranatom C1-C3 tioalkil grupom; ili ravna ili razgranata C1-C4 tioalkil grupa nesupstituirana ili supstituirana sa ravnom ili razgranatom C1-C5 alkil grupom, atomom halogena, ravnom ili razgranatom C1-C5 alkoksi grupom, ili ravnom ili razgranatom C1-C3 tioalkil grupom;
The lamellas 3 and 4 preferably overlap over a distance of ¾ of the length of short side 6 . 
Poželjno je da se lamele preklapaju duž razmaka od 3/4 duljine kratke strane 6.
A particle contrast agent composition is disclosed for staining a blood fluid sample being imaged in an automated particle analysis system. The particle contrast agent composition can include at least one particle contrast agent selected from the group consisting of Crystal Violet, New Methylene Blue, Methyl Green, Eosin Y, and Safranin O. The particle contrast agent composition can further include a permeabilizing agent selected from the group consisting of a surfactant, a saponin, a quarternary ammonium salt, a nonionic surfactant, a detergent; and a zwitterionic surfactant. 
PATENTNI ZAHTJEVI Pripravak sredstva za kontrast čestica za bojenje uzorka krvnog fluida koji će biti prikazan pomoću automatiziranog sustava za analizu čestica koji sadrži: barem dva sredstva za kontrast čestica koja su odabrana iz skupine koju čine Kristal violet, Novo metilensko modrilo, Metil zeleno, Eozin Y, i Safranin O; sredstvo za permeabilizaciju koje obuhvaća saponin prisutan u dovoljnoj količini da se dobiju koncentracije između oko 50 mg/L i oko 750 mg/L. u uvjetima bojenja; i sredstvo za fiksiranje odabrano iz skupine koju čine glutaraldehid i formaldehid.
A lead composition comprising solid lead having a purity of at least 98%, molecular hydrogen, and a lead ion-enriched electroprocessing solvent which is an aqueous solution comprising an alkane sulfonic acid, a chelator, and has a pH of less than 7, wherein the solid lead, the hydrogen, and the electroprocessing solvent form a micro- or nanoporous mixed matrix having a density of less than 5 g/cm3, wherein the pH of the electroprocessing solvent is less than 7. 
Olovna supstanca koja sadrži kruti oblik olova s čistoćom od najmanje 98%, molekularnim vodikom, i ionom olova obogaćeno elektroprocesorsko otapalo koje je vodeno otapalo koje sadrži alkan sulfonsku kiselinu, kelator, i ima pH manji od 7, pri čemu kruti oblik olova, vodik, i elektroprocesorsko otapalo tvori mikroporoznu ili nanoporoznu miješanu matricu gustoće manje od 5 g/em', pri čemu je pH obogaćenog elektroprocesorskog otapala HR P20190579 T1 manji od 7.
The insert for soles according to claim 1, wherein the insert for soles has a tear strength of at least 10 N, determined according to the method presented in the EN13571 standard. 
Umetak za potplate u skladu s patentnim zahtjevom 1, naznačen time, da ima otpornost na trganje od najmanje 10 N, određeno prema postupku koji je opisan u EN13571 standardu.
In preferred embodiment, the compound which inhibits the NKCC co-transporter is a diuretic. 
Spoj za uporabu u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što spoj je diuretik.
In the following example 14 the dry powder composition of thyroid hormone is identical with the composition of the tablets of the example 1 of the patent document US-A1-2004/0033259, herein fully incorporated by reference. 
C) U sljedećem primjeru 14 pripravak suhog praha s tiroidnim hormonom je identičan sa sastavom tableta iz primjera 1 patentnog dokumenta US-A1-2004/0033259.
The resulting solution is brought to basic pH by adding NaOH(s), and stirred at room temperature while bubbling an air stream through the solution for 10 hours. 
Dobivenu otopinu se zaluži dodatkom NaOH 1 miješa se 10 sati pri sobnoj temperaturi uz propuštanje mjehurića zraka kroz otopinu.
The sustained release composition of any one of claims 1 to 5, which is in the form of microparticles. 
Oblik za produljeno oslobađanje prema bilo kojem od zahtjeva 1 do 5, a koji je u obliku mikročestica.
A compound of claim 2 selected from the group consisting of: 
Spoj, naznačen time, da je odabran iz skupine koju čine:
The composition for use according to claim 5, wherein the treatment further comprises a step of determining whether the patient has CMT1A. 
Sastav za uporabu u skladu s patentnim zahtjevom 5, pri čemu liječenje nadalje obuhvaća korak određivanja ima li pacijent CMTIA.
On the other hand, when the resilient nature is due to the material used and a “filled” sealing member is used, usually a compression and/or displacement of the material occur. The sealing surface 15 according to this embodiment is inclined. 
S druge strane, kada se postiže elastičnost, kao što je definirano u patentnim zahtjevima, zbog materijala koji se koristi, i kada se koristi "ispunjeni" element za nepropusno zatvaranje, obično se javlja stlačivanje i/ili pomak materijala.